rs267607976
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000251.3(MSH2):c.1759+2T>A variant causes a splice donor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★★).
Frequency
Consequence
NM_000251.3 splice_donor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1231242Hom.: 0 Cov.: 19 AF XY: 0.00 AC XY: 0AN XY: 624270
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Lynch syndrome Pathogenic:1
Multifactorial likelihood analysis posterior probability >0.99 -
not provided Pathogenic:1
- -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. This sequence change affects a donor splice site in intron 11 of the MSH2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with clinical features of Lynch syndrome (PMID: 11772966, 12436451, 16034045). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 90767). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.1759+2T>A intronic pathogenic mutation results from a T to A substitution two nucleotides after coding exon 11 of the MSH2 gene. This mutation has been reported in multiple HNPCC/Lynch syndrome families with tumor results demonstrating high microsatellite instability (MSI-H) and/or loss of MSH2 expression on immunohistochemistry (IHC) (Katballe N et al. Gut. 2002 Jan;50:43-51; Christensen M et al. Cancer. 2002 Dec;95:2422-30; Stormorken AT et al. J. Clin. Oncol. 2005 Jul;23:4705-12; Sjursen W et al. J. Med. Genet. 2010 Sep;47:579-85). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at